The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes

European Journal of Surgical Oncology

Volumn 22, Issue 2, 1996, Pages 123-127

  Cascinelli, N ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b WHO Melanoma Programme   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; ELECTIVE SURGERY; HUMAN; LYMPH NODE DISSECTION; MELANOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

EID: 0029920848     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)90463-1     Document Type: Article

References (49)

1. Bodenham DC. A study of 650 observed malignant melanomas in the South-West Region. Ann Roy Coll Surg Engl 1968; 43: 218.
2. Olsen G. The malignant melanoma of the skin. New theories based on a study of 500 cases. Acta Chir Scan 1966; Suppl. 365: Thesis.
3. Pack GT. End results in the treatment of malignant melanoma. Surgery 1959; 46: 447.
4. Pack GT, Scharnagel I, Morfit M. The principle of excision and dissection in continuity for primary and metastatic melanoma of the skin. Surgery 1945; 17: 849.
5. McNeer G. Clinic on melanoma. Panel discussion. In Della Porta G, Muhlbock O (eds) Structures and Control of the Melanocyte, Sixth International Pigment Cell Conference (Sofia, Bulgaria, 1965) 1966: 358-74.
6. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. New Engl J Med 1977; 297: 627-30.
7. Veronesi U, Adamus J, Bandiera D, et al. Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori 1980; 66: 373-96.
8. Balch CM, Milton GW, Cascinelli N, Sim FH. Elective lymph node dissection: pros and cons. In Balch CM, Houghton AN. Milton GW. Sober AJ, Soon SJ (eds) Cutaneous Melanoma (2nd Edn) Philadelphia: JB Lippincott Company 1992:345-66.
9. Cascinelli N. Unpublished data.
10. Karakousis C. Data presented at the Internationales Symposium Malignes Melanom - Aktueler Stand von Diagnose und Therapie. Erlangen (Germany), January 26-27, 1996.
11. Morton D, Wen DR, Wong JH, et al Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992; 127: 392-9.
12. Krag DN, Sybren JM, Weaver DL. Minimal access surgery for staging of malignant melanoma. Arch Surg 1995; 130: 654-8.
13. Reintgen D, Wayne Cruse C, Wells K. The orderly progression of nodal metastases. Ann Surg 1994; 220: 1994; 759-67.
14. Morton DL, Wen DR, Foshag LJ, et al. Intraoperative lymphatic mapping and selected cervical lymphadenectomy for early stage melanomas of the head and neck. J Clin Oncol 1993; 11: 1751-6.
15. Handley WS. The pathology of melanotic growth in relation to their operative treatment. Lancet 1907; i: 966.
16. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.
17. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biological behaviour of primary tumor malignant melanoma of the skin. Cancer Res 1969; 29.
18. Everall JD, Dowd PM. Diagnosis, prognosis and treatment of melanoma (a review). Lancet 1977; ii: 286.
19. Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynec Obstet 1977; 145: 691.
20. Balch CM, Murad TM, Sonng SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer (Philadelphia) 1979; 43: 883.
21. WHO Collaborating Centres for Evaluating of Methods of Diagnosis and Treatment of Melanoma, Cascinelli N, van der Esch RP, Breslow A, Morabito A, Bufalino R. Stage I melanoma of the skin: the problem of resection margins. Eur J Cancer 1980; 16: 1079-85.
22. Veronesi U, Cascinelli N. Narrow excision (1 cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-41.
23. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2 cm surgical margins for intermediate thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-9.
24. Schabel FM. Animal models as predictive systems. In: Allfrey VG, Allgower M, Berenblum I, et al. (eds) Cancer Chemotherapy: fundamental concepts and recent advances. Chicago: Year Book, 1975: 323-55.
25. Silver RT, Young RC, Holland JF. Some new aspects of modern cancer chemotherapy. Am J Med 1977; 63: 772-87.
26. Baldwin RW, Pimm MV. BCG immunotherapy of local subcutaneous growth and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer 1973; 12: 420-7.
27. Sparks FC, O'Connell TX, Lee YTN. Adjuvant preoperative and postoperative immunochemotherapy for mammary adenocarcinoma in rats. Surg Forum 1973; 24: 118-21.
28. Levy JG, Whitney RB, Smith AG, Panno L. The relationship of immune status to the efficacy of immunotherapy in preventing tumor recurrence in mice. Br J Cancer 1974; 30: 289-96.
29. Morton DL. Immunotherapy of cancer: present and future potential. Cancer 1972; 30: 1647-55.
30. Morton DL, Eilber FR, Holmes EC. Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol Immunother 1976; 1: 93-8.
31. Gutterman JU, McBride C, Freireich EJ, Mavligit G, Frei E III, Hersch EM. Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1973; 1: 1208-12.
32. Serrou B, Pujol H, Domas J, Gauci L. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III - V) treated by post-surgical chemoimmunotherapy. Recent Results. Cancer Res 1979; 68: 363-6.
33. Hedley DW, McElwain TJ, Currie GA. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer 1978; 37: 491-6.
34. Mclllmurray MB, Embleton MJ, Reeves WG, Langmar MJS, Deane M. Controlled trial of active immunotherapy in management of stage 2B malignant melanoma. Br Med J 1977; 1: 540-2.
35. Hill GJ, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma. Cancer 1981; 47: 2556-62.
36. Jaquillat C, Banzet P, Civatte J, et al. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV or V. Recent Results Cancer Res 1979; 68: 346-58.
37. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 1982; 307: 913-6.
38. Cascinelli N, Rumke P, MacKie R. Morabito A, Bufalino R. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after surgery in stage II melanoma patients. Cancer Immunol Immunother 1989; 28: 282-6.
39. Cascinelli N. Unpublished data.
40. Cascinelli N, Bufalino R, Morabito A, MacKie R, on behalf of the WHO Melanoma Programme. Results of adjuvant Interferon study in WHO Melanoma Programme. Letter to the Editor. The Lancet 1994; 343: 913-4.
41. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant Interferon alfa-2A in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2276-83.
42. Kirkwood JM, Hunt Strawderman M, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14: 7-17.
43. Santinami M, Belli F, Cascinelli N, Rovini D, Vaglini M. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 1989; 42: 201-8.
44. Cavaliere R, Cavaliere F, Deraco M, Di Filippo F, Santinami M, Vaglini M. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. Melanoma Res 1993; 4 (Suppl. 1): 5-12.
45. Stehlin S, Giovannella BC, De Ipolyi D, et al. Results of hyperthermic perfusion of melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339-48.
46. Krementz ET. Regional perfusion. Current sophistication, what next? Cancer 1986; 57: 416-32.
47. Schraffordt Koops HS, Oldhoff J. Hyperthermic regional perfusion in high-risk stage I malignant melanomas of the extremities. Recent Results Cancer Res 1983; 86: 223-8.
48. Jonsson PE, Hafstrom LO, Ingvar C, Olsson H, Jonsson N. Adjuvant regional hyperthermic perfusion versus no perfusion in high risk primary melanoma on the extremities (Meeting Abstract). First International Conference on Skin Melanoma (Venice, May 6-9, 1985). Short Talks and Poster: abstract 91, 1985.
49. Martijn H, Schraffordt Koops H, Milton GW, et al. Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 1986; 57: 1923-30.